Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor

Molecular and Cellular Endocrinology

Volumn 126, Issue 1, 1997, Pages 59-73

  Heisler, Lawrence E ^a   Evangelou, Andreas ^b   Lew, April M ^b   Trachtenberg, John ^a   Elsholtz, Harry P ^b   Brown, Theodore J ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen receptor; Apoptosis; Cell proliferation; Human prostate cancer cells; PC 3 cells; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; COMPLEMENTARY DNA; DNA FRAGMENT; HYDROXYFLUTAMIDE; LUCIFERASE;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA DEGRADATION; DNA TRANSFECTION; EXPRESSION VECTOR; GENE INDUCTION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIGAND BINDING; MITOSIS INHIBITION; MOUSE MAMMARY TUMOR ONCOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; REPORTER GENE;

ANDROGENS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL NUCLEUS; DIHYDROTESTOSTERONE; GENE EXPRESSION; HUMANS; LUCIFERASES; MALE; MAMMARY TUMOR VIRUS, MOUSE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031024251     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(96)03970-6     Document Type: Article

References (59)

1. Lesser, B. and Bruchovsky, N. (1973) The effects of testosterone, 5α-dihydrotestosterone and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in rat prostate. Biochim. Biophys. Acta 308, 426-437.
2. Kyprianou, N. and Isaacs, J.T. (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122, 552-562.
3. Tenniswood, M.P., Guenette, R.S., Lakins, J., Moolbroek, M., Wong, P. and Welsh, J.-E. (1992) Active cell death in hormone-dependent tissues. Cancer Metastasis Rev. 11, 197-220.
4. Hucher, M., De Gery, A. and Bertagna, C. (1993) Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients: Overview of seven randomized placebo controlled studies. Cancer 72 (Suppl.), 3886-3887.
5. Dalesia, O. (1992) Complete androgen blockade in prostate cancer: an overview of randomized trials. Prostate 4 (Suppl.), 111-114.
6. Cookson, M.S. and Sarosdy, M.F. (1994) Hormonal therapy for metastatic prostate cancer: Issues of timing and total androgen ablation. South Med. J. 87, 1-6.
7. Sato, N., Watabe, Y., Suzuki, H. and Shimazaki, J. (1993) Progression of androgen-sensitive mouse tumor (Shionogi Carcinoma 115) to androgen-insensitive tumor after long-term removal of testosterone. Jpn. J. Cancer Res. 84, 1300-1308.
8. Ruizeveld de Winter, J.A., Janssen, P.J.A., Sleddens, H.M.E.B., Verleun-Mooijman, M.C.T., Trapman, J., Brinkmann, A.O., Santerse, A.B., Schröder, F.H. and Van der Kwast, T.H. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 144, 735-746.
9. Van der Kwast, T.H., Schalken, J., Ruizeveld de Winter, J.A., Van Vroonhoven, C.C.J., Mulder, E., Boersma, W. and Trapman, J. (1991) Androgen receptors in endocrine-therapy resistant human prostate cancer. Int. J. Cancer 48, 189-193.
10. Tilley, W.D., Bentel, J.M., Aspinall, J.O., Hall, R.E. and Horsfall, D.J. (1995) Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids 60, 180-136.
11. Tilley, W.D., Wilson, C.M., Marcelli, M. and McPhaul, M.J. (1990) Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 50, 5382-5386.
12. Kozlowski, J.M., Fidler, I.J., Campbell, D., Xu, D.L., Kaighn, M.E. and Hart, I.R. (1984) Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 44, 3522-3529.
13. Ware, J.L., Paulson, D.F., Mickey, G.H. and Webb, K.S. (1982) Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J. Urol. 128, 1064-1067.
14. Yuan, S., Trachtenberg, J., Mills, G.B., Brown, T.J., Xu, F. and Keating, A. (1993) Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res. 53, 1304-1311.
15. Marcelli, M., Haidacher, S.J., Stephen, R.P. and Birnbaum, R.S. (1995) Altered growth and insulin-like growth factor-binding protein-3 production in PC-3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 136, 1040-1048.
16. Hansen, N.M., Chang, C., Chodak, G.W. and Rukstalis, D.B. (1991) Modulation of hormone sensitivity in PC3 cells by transfection of a normal human androgen receptor. Surg. Forum 43, 745-748.
17. Zajchowski, D.A., Sager, R. and Webster, L. (1993) Estrogen inhibits the growth of estrogen receptor negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res. 53, 5004-5011.
18. Kushner, P.J., Hort, E., Shine, J., Baxter, J.D. and Greene, G.L. (1990) Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol. Endocrinol. 4, 1465-1473.
19. Jeng, M., Jiang, S. and Jordan, V.C. (1994) Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett. 82, 123-128.
20. Levenson, A.S. and Jordan, V.C. (1994) Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J. Steroid Biochem. Mol. Biol. 51, 229-239.
21. Meyer, M.E., Gronemeyer, H., Turcotte, B., Bocquel, M.-T., Tasset, D. and Chambon, P. (1989) Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57, 433-442.
22. Jones, S.A., Brooks, A.N. and Challis, J.R.G. (1989) Steroids modulate corticotropin-releasing hormone production in human fetal membranes and placenta. J. Clin. Endocrinol. Metab. 68, 825-830.
23. Chang, C., Kokontis, J. and Liao, S. (1988) Structural analysis of complimentary DNA and amino acid sequences of human and rat androgen receptors. Proc. Natl. Acad. Sci. USA 85, 7211-7215.
24. Sanbrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd. edn, Cold Spring Harbor Laboratory Press, New York.
25. 2 receptor-regulated expression of the prolactin gene. J. Biol. Chem. 266, 22919-22925.
26. Hollenberg, S.M. and Evans, R.M. (1988) Mutiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell 55, 899-906.
27. Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J. and Klenk, D.C. (1985) Measurement of protein using bicinchonic acid. Anal. Biochem. 150, 76-85.
28. Puy, L., MacLusky, N.J., Becker, L., Karsan, N., Trachtenberg, J. and Brown, T.J. (1995) Immunocytochemical detection of androgen receptor in human temporal cortex: characterization and application of polyclonal androgen receptor antibodies in frozen and paraffin-embedded tissues. J. Steroid Biochem. Mol. Biol. 55, 197-209.
29. 3H]methyltrienolone (R1881) in the presence of progesterone receptors. Endocrinology 104, 1007-1013.
30. Brolin, J., Skoog, L. and Ekman, P. (1992) Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 20, 281-295.
31. Ginsburg, M., Greenstein, B.D., MacLusky, N.J., Morris, I.D. and Thomas, P.J. (1974) An improved method for the study of high affinity steroid binding: oestradiol binding in brain and pituitary. Steroids 23, 773-792.
32. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principal of protein-dye binding. Anal. Biochem. 42, 248-254.
33. Scatchard, G. (1949) The attraction of proteins for small molecules and ions. Ann. NY Acad. Sci. 51, 660-672.
34. Munson, P.J. and Rodbard, D. (1980) LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107, 220-239.
35. Burton, K. (1955) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62, 315-323.
36. Romijn, J.C., Verkoelen, C.F. and Schroeder, F.H. (1988) Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12, 99-110.
37. Gong, J., Traganos, F. and Darzynkiewicz, Z. (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal. Biochem. 218, 314-319.
38. Schuurmans, A.L.G., Bolt, J., Voorhorst, M.M., Blankenstein, R.A. and Mulder, E. (1988) Regulation of growth and epidermal growth factor receptor levels in LNCaP prostate tumor cells by different steroids. Int. J. Cancer 42, 917-922.
39. Nakhla, A.M. and Rosner, W. (1994) Characterization of ALVA-41 cells, a new human prostatic cancer cell line. Steroids 59, 586-589.
40. Brass, A.L., Barnard, J., Patai, B.L., Salvi, D. and Rukstalis, D.B. (1995) Androgen up-regulates epidermal growth receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res. 55, 3197-3203.
41. Webb, P., Lopez, G.N., Greene, G.L., Baxter, J.D. and Kushner, P.J. (1992) The limits of the cellular capacity to mediate an estrogen response. Mol. Endocrinol. 6, 157-167.
42. Watts, C.K.W. and King, R.J.B. (1994) Overexpression of estrogen receptor in HTB 96 human osteosarcoma cells results in estrogen-induced growth inhibition and receptor cross talk. J. Bone Miner. Res. 9, 1251-1258.
43. Hoeck, W., Hofer, P. and Groner, B. (1992) Overexpression of the glucocorticoid receptor represses transcription from hormone responsive and non-responsive promoters. J. Steroid Biochem. Mol. Biol. 41, 283-289.
44. Novichenko, N., Konno, S., Nakjima, Y., Hsieh, T.C., Xu, W., Turo, K., Aumed, T. and Chiao, J.W. (1995) Growth attenuation in a human prostate cell line mediated by a phorbol ester. PSEBM 209, 152-156.
45. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M.A., Lassota, P. and Traganos, F. (1992) Features of apoptotic cells measured by flow cytometry. Cytometry 13, 795-808.
46. Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F. and Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271-279.
47. Power, R.F., Conneely, O.M. and O'Malley, B.W. (1992) New insights into activation of the steroid hormone receptor superfamily. Trends Pharmacol. Sci. 13, 318-323.
48. Ignar-Trowbridge, D.M., Nelson, K.G., Bidwell, M.C., Curtis, S.W., Washburn, T.F., McLachlin, J.A. and Korach, K. S. (1992) Coupling of dual signalling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA 89, 4658-4662.
49. Culig, Z., Hobisch, A., Cronauer, M.V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G. and Klocker, H. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474-5478.
50. Labrie, F., Dupont, A., Simard, J., Luu-The, V. and Belanger, A. (1993) Intracrinology: The basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol. 24 (Suppl. 2), 94-105.
51. Scher, H.I. and Kelly, W.K. (1993) Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11, 1566-1572.
52. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W.D., Lineban, W.M. and Myers, C.E. (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of 'hormone-refractory' prostate cancer. J. Natl. Cancer. Inst. 86, 222-227.
53. Dupont, A., Gomez, J., Cusan, L., Koutsilieris, M. and Labrie, F. (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 150, 908-913.
54. Kelly, W.K., Scher, H.I., Mazumdar, M., Vlamis, V., Schwartz, M. and Fossa, S.D. (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 11, 607-615.
55. Veldscholte, J., Ris-Stalpers, C., Kuiper, G.G.J.M., Jenster, G., Berrevoets, C., Claassen, E., Van Rooij, H.C.J., Trapman, J., Brinkmann, A.O. and Mulder, E. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534-540.
56. Berrevoets, C.A., Veldscholte, J. and Mulder, E. (1993) Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J. Steroid Biochem. Mol. Biol. 46, 731-736.
57. Quigley, C.A., De Bellis, A., Marschke, K.B., El-Awady, M.K., Wilson, E.M. and French, F.S. (1995) Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16, 271-320.
58. Tilley, W.D., Buchanan, G., Hickey, T.E. and Bentel, J.M. (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2, 277-285.
59. Taplan, M.-E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N. and Balk, S.P. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398.